Retraction: "The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB signaling [Molecular and Cellular Biology, 32, 22, (2012), (4662-4773)] doi: 10.1128/MCB.00935-12;The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB signaling

Molecular and Cellular Biology

Volumn 32, Issue 22, 2012, Pages 4662-4673

  Wei, Wangzhi ^a,b   Liu, Wei ^a,b   Cassol, Clarissa A ^a,b   Zheng, Weiyue ^a   Asa, Sylvia L ^a,b   Ezzat, Shereen ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE TRANSLOCATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84869023217     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00298-18     Document Type: Erratum

References (35)

1. Baraniak AP, Lasda EL, Wagner EJ, Garcia-Blanco MA. 2003. A stem structure in fibroblast growth factor receptor 2 transcripts mediates celltype-specific splicing by approximating intronic control elements. Mol. Cell. Biol. 23:9327-9337.
2. Barkett M, Gilmore TD. 1999. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18:6910-6924.
3. Berishaj M, et al. 2007. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 9:32-38.
4. Bromberg JF, et al. 1999. Stat3 as an oncogene. Cell 98:295-303.
5. Chan KS, et al. 2004. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. 114:720 -728.
6. Darnell JE, Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
7. Drafahl KA, McAndrew CW, Meyer AN, Haas M, Donoghue DJ. 2010. The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling. PLoS One 5:e14412. doi:10.1371/journal.pone.0014412.
8. Easton DF, et al. 2007. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087-1093.
9. Foubert E, De Craene B, Berx G. 2010. Key signaling nodes in mammary gland development and cancer: the Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res. 12:206. doi:10.1186/ bcr2585.
10. Gilmore TD. 2006. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25:6680-6684.
11. Givol D, Yayon A. 1992. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J. 6:3362-3369.
12. Häcker H, Karin M. 2006. Regulation and function of IKK and IKKrelated kinases. Sci. STKE 2006(357):re13. doi:10.1126/stke.3572006re13.
13. Hunter DJ, et al. 2007. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39:870-874.
14. Iliopoulos D, Hirsch HA, Struhl K. 2009. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139:693-706.
15. Jacobs MD, Harrison SC. 1998. Structure of an IkappaBalpha/NFkappaB complex. Cell 95:749 -758.
16. Johnston CL, Cox HC, Gomm JJ, Coombes RC. 1995. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J. Biol. Chem. 270: 30643-30650.
17. Karin M. 1999. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18:6867- 6874.
18. Karin M. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441:431- 436.
19. Kim Y, Kang H, Jang SW, Ko J. 2011. Celastrol inhibits breast cancer cell invasion via suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Cell. Physiol. Biochem. 28:175-184.
20. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. 2003. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz. Akad. Med. Bialymst. 48:82- 84.
21. Lee JM, Dedhar S, Kalluri R, Thompson EW. 2006. The epithelialmesenchymal transition: new insights in signaling, development and disease. J. Cell Biol. 172:973-981.
22. Logullo AF, et al. 2010. Concomitant expression of epithelialmesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol. Rep. 23:313-320.
23. Luo Y, Ye S, Kan M, McKeehan WL. 2006. Structural specificity in a FGF7-affinity purified heparin octasaccharide required for formation of a complex with FGF7 and FGFR2IIIb. J. Cell. Biochem. 97:1241-1258.
24. Meyer KB, et al. 2008. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 6:e108. doi:10.1371/ journal.pbio.0060108.
25. Salgado R, et al. 2003. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 103:642- 646.
26. Sullivan NJ, et al. 2009. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28:2940- 2947.
27. Thisse B, Thisse C, Weston JA. 1995. Novel FGF receptor (Z-FGFR4) is dynamically expressed in mesoderm and neurectoderm during early zebrafish embryogenesis. Dev. Dyn. 203:377-391.
28. Thisse B, Thisse C. 2005. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev. Biol. 287:390-402.
29. Tobin NP, Sims AH, Lundgren KL, Lehn S, Landberg G. 2011. Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer 11:417. doi:10.1186/ 1471-2407-11-417.
30. Yan G, et al. 1992. Expression and transforming activity of a variant of the heparin-binding fibroblast growth factor receptor (flg) gene resulting from splicing of the alpha exon at an alternate 3=-acceptor site. Biochem. Biophys. Res. Commun. 183:423- 430.
31. Yeh PY, Lu YS, Ou DL, Cheng AL. 2011. IκB kinases increase Myc protein stability and enhance progression of breast cancer cells. Mol. Cancer 10:53.
32. Zhan L, et al. 2008. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 135:865- 878.
33. Zhang X, et al. 2011. Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc. Natl. Acad. Sci. U. S. A. 109:2790 -2795.
34. Zhu X, Asa SL, Ezzat S. 2009. Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol. Endocrinol. 23:1397-1405.
35. Zhu X, Zheng L, Asa SL, Ezzat S. 2010. Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphisms to direct allelic selection in breast cancer. Am. J. Pathol. 177:2860- 2869.